WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326761
CAS#: 863329-66-2
Description: GS-331007, also known as PSI-6206 and RO-2433, is a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Hodoodo Cat#: H326761
Name: GS-331007 (PSI-6206)
CAS#: 863329-66-2
Chemical Formula: C10H13FN2O5
Exact Mass: 260.08
Molecular Weight: 260.221
Elemental Analysis: C, 46.16; H, 5.04; F, 7.30; N, 10.77; O, 30.74
Synonym: RO-2433; RO 2433; RO2433; PSI6206; PSI-6206; PSI 6206; GS331007; GS-331007; GS 331007.
IUPAC/Chemical Name: 1-((2R,3R,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyl-tetrahydrofuran-2-yl)pyrimidine-2,4-dione
InChi Key: ARKKGZQTGXJVKW-VPCXQMTMSA-N
InChi Code: InChI=1S/C10H13FN2O5/c1-10(11)7(16)5(4-14)18-8(10)13-3-2-6(15)12-9(13)17/h2-3,5,7-8,14,16H,4H2,1H3,(H,12,15,17)/t5-,7-,8-,10-/m1/s1
SMILES Code: O=C1NC(C=CN1[C@@H]2O[C@H](CO)[C@@H](O)[C@]2(F)C)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 260.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Lawitz E, Rodriguez-Torres M, Denning JM, Albanis E, Cornpropst M, Berrey MM,
Symonds WT. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a
nucleotide analog polymerase inhibitor, following multiple ascending doses in
patients with chronic hepatitis C infection. Antimicrob Agents Chemother. 2013
Mar;57(3):1209-17. doi: 10.1128/AAC.01263-12. Epub 2012 Dec 21. PubMed PMID:
23263000; PubMed Central PMCID: PMC3591915.
2: Denning J, Cornpropst M, Flach SD, Berrey MM, Symonds WT. Pharmacokinetics,
safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for
hepatitis C virus, following single ascending doses in healthy subjects.
Antimicrob Agents Chemother. 2013 Mar;57(3):1201-8. doi: 10.1128/AAC.01262-12.
Epub 2012 Dec 21. PubMed PMID: 23262999; PubMed Central PMCID: PMC3591883.
3: Murakami E, Niu C, Bao H, Micolochick Steuer HM, Whitaker T, Nachman T, Sofia
MA, Wang P, Otto MJ, Furman PA. The mechanism of action of
beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway
leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent
inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob
Agents Chemother. 2008 Feb;52(2):458-64. Epub 2007 Nov 12. PubMed PMID: 17999967;
PubMed Central PMCID: PMC2224766.
4: Asif G, Hurwitz SJ, Shi J, Hernandez-Santiago BI, Schinazi RF.
Pharmacokinetics of the antiviral agent
beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys. Antimicrob
Agents Chemother. 2007 Aug;51(8):2877-82. Epub 2007 Jun 11. PubMed PMID:
17562805; PubMed Central PMCID: PMC1932527.
